

## **KURZPROTOKOLL** **OlympiA**

<b>Öffentlicher Titel</b>	Phase III Studie zu Olaparib als adjuvante Therapie bei BRCA-Mutation und Her2-negativem primären Brustkrebs mit hohem Risiko
<b>Wissenschaftl. Titel</b>	A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
<b>Kurztitel</b>	OlympiA
<b>Studienart</b>	multizentrisch, Therapiestudie, randomisiert, doppelblind, zweiarmig, kontrolliert
<b>Studienphase</b>	Phase III
<b>Erkrankung</b>	Geschlechtsorgane: Brustkrebs: adjuvant
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- Histologically confirmed non-metastatic primary triple negative invasive adenocarcinoma of the breast. •Invasive Triple Negative Breast Cancer</li><li>- Documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function).</li><li>- Completed adequate breast and axilla surgery.</li><li>- Completed at least 6 cycles neoadjuvant or adjuvant chemotherapy containing anthracyclines, taxanes or the combination of both. Prior platinum as potentially curative</li><li>- ECOG 0-1.</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- Any previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment.</li><li>- Patients with second primary cancer, EXCEPTIONS: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, Ductal Carcinoma in situ (DCIS) of the breast, stage 1 grade 1 endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for 5 years prior to randomization. More than one course of chemotherapy for previous malignancies.</li><li>- Resting ECG with QTc &gt; 470 msec detected on 2 or more time points within a 24 hour period or family history of long QT syndrome. If ECG demonstrates QTc &gt;470 msec, patient will be eligible only if repeat ECG demonstrates QTc 470 msec.</li><li>- Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.</li><li>- Whole blood transfusions in the last 120 days prior to entry to the study which may interfere with gBRCA testing</li></ul>
<b>Alter</b>	18 Jahre und älter
<b>Molekularer Marker</b>	BRCA Triple neg (HER2/ER/PR neg) HER2/neu neg./ER pos. HER2/neu neg./PR pos.
<b>Fallzahl</b>	1320
<b>Prüfzentren</b>	<b>Sana Klinikum Offenbach</b> (Rekrutierung beendet) Ambulantes Onkologisches Zentrum Starkenburgring 66 63069 Offenbach n.a. Melanie Moschitz Tel: 069 8405 5815 Fax: 069 8405 4486 <a href="mailto:Melanie.Moschitz@sana.de">Melanie.Moschitz@sana.de</a>

**KURZPROTOKOLL**  
**OlympiA**

**Klinikum Frankfurt Höchst** (Rekrutierung beendet)

Klinik für Gynäkologie und Geburtshilfe

Gotenstraße 6-8

65929 Frankfurt am Main

Prof. Dr. Joachim Rom

[joachim.rom@varisano.de](mailto:joachim.rom@varisano.de)

**MVZ-Osthessen GmbH** (Rekrutierung beendet)

Onkologisches Zentrum

Pacelliallee 4

36043 Fulda

Prof. Dr. med. Heinz-Gert Höffkes

Tel: 0661 845487

Fax: 0661 845484

[hoeffkes.tumorklinik@klinikum-fulda.de](mailto:hoeffkes.tumorklinik@klinikum-fulda.de)

**Sponsor**

Astra Zeneca

**Registrierung in anderen  
Studienregistern**

EudraCT 2013-003839-30

ClinicalTrials.gov NCT02032823